Pathophysiology of COVID-19: Why Children Fare Better than Adults?
- PMID: 32410003
- PMCID: PMC7221011
- DOI: 10.1007/s12098-020-03322-y
Pathophysiology of COVID-19: Why Children Fare Better than Adults?
Abstract
The world is facing Coronavirus Disease-2019 (COVID-19) pandemic, which is causing a large number of deaths and burden on intensive care facilities. It is caused by Severe Acute Respiratory Syndrome coronavirus-2 (SARS-CoV-2) originating in Wuhan, China. It has been seen that fewer children contract COVID-19 and among infected, children have less severe disease. Insights in pathophysiological mechanisms of less severity in children could be important for devising therapeutics for high-risk adults and elderly. Early closing of schools and day-care centers led to less frequent exposure and hence, lower infection rate in children. The expression of primary target receptor for SARS-CoV-2, i.e. angiotensin converting enzyme-2 (ACE-2), decreases with age. ACE-2 has lung protective effects by limiting angiotensin-2 mediated pulmonary capillary leak and inflammation. Severe COVID-19 disease is associated with high and persistent viral loads in adults. Children have strong innate immune response due to trained immunity (secondary to live-vaccines and frequent viral infections), leading to probably early control of infection at the site of entry. Adult patients show suppressed adaptive immunity and dysfunctional over-active innate immune response in severe infections, which is not seen in children. These could be related to immune-senescence in elderly. Excellent regeneration capacity of pediatric alveolar epithelium may be contributing to early recovery from COVID-19. Children, less frequently, have risk factors such as co-morbidities, smoking, and obesity. But young infants and children with pre-existing illnesses could be high risk groups and need careful monitoring. Studies describing immune-pathogenesis in COVID-19 are lacking in children and need urgent attention.
Keywords: ACE-2; Adaptive immunity; Innate immunity; Pathogenesis; SARS-CoV2.
Conflict of interest statement
None.
Similar articles
-
Why COVID-19 Transmission Is More Efficient and Aggressive Than Viral Transmission in Previous Coronavirus Epidemics?Biomolecules. 2020 Sep 11;10(9):1312. doi: 10.3390/biom10091312. Biomolecules. 2020. PMID: 32933047 Free PMC article. Review.
-
The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status.Mil Med Res. 2020 Mar 13;7(1):11. doi: 10.1186/s40779-020-00240-0. Mil Med Res. 2020. PMID: 32169119 Free PMC article. Review.
-
Why is SARS-CoV-2 infection milder among children?Clinics (Sao Paulo). 2020;75:e1947. doi: 10.6061/clinics/2020/e1947. Epub 2020 May 15. Clinics (Sao Paulo). 2020. PMID: 32428111 Free PMC article. No abstract available.
-
Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19).J Pathol. 2020 Jul;251(3):228-248. doi: 10.1002/path.5471. Epub 2020 Jun 10. J Pathol. 2020. PMID: 32418199 Free PMC article. Review.
-
Are children less susceptible to COVID-19?J Microbiol Immunol Infect. 2020 Jun;53(3):371-372. doi: 10.1016/j.jmii.2020.02.011. Epub 2020 Feb 25. J Microbiol Immunol Infect. 2020. PMID: 32147409 Free PMC article. No abstract available.
Cited by
-
Novel coronavirus disease 2019 (COVID-19) pandemic: From transmission to control with an interdisciplinary vision.Environ Res. 2021 Jun;197:111126. doi: 10.1016/j.envres.2021.111126. Epub 2021 Apr 5. Environ Res. 2021. PMID: 33831411 Free PMC article. Review.
-
COVID-19: Why does disease severity vary among individuals?Respir Med. 2021 Apr-May;180:106356. doi: 10.1016/j.rmed.2021.106356. Epub 2021 Mar 5. Respir Med. 2021. PMID: 33713961 Free PMC article. Review.
-
COVID-19 in the Pediatric Population-Review and Current Evidence.Curr Infect Dis Rep. 2020;22(11):29. doi: 10.1007/s11908-020-00739-6. Epub 2020 Sep 19. Curr Infect Dis Rep. 2020. PMID: 32982599 Free PMC article. Review.
-
COVID-19 and obesity in childhood and adolescence: a clinical review.J Pediatr (Rio J). 2020 Sep-Oct;96(5):546-558. doi: 10.1016/j.jped.2020.07.001. Epub 2020 Aug 4. J Pediatr (Rio J). 2020. PMID: 32768388 Free PMC article. Review.
-
Sex- and age-specific clinical and immunological features of coronavirus disease 2019.PLoS Pathog. 2021 Mar 26;17(3):e1009420. doi: 10.1371/journal.ppat.1009420. eCollection 2021 Mar. PLoS Pathog. 2021. PMID: 33770147 Free PMC article.
References
-
- WHO COVID-19 Dashboard. Available at: https://covid19.who.int/. Accessed 21 Apr 2020.
-
- Coronavirus Disease 2019 (COVID-19). Available at: https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/04102020/.... Accessed 14 April 2020.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous